欢迎您！东篱公司
退出
-
申报数据库
-
立项数据库
-
成果数据库
-
项目获奖数据库
中文摘要：
将雄性小鼠随机分成对照组、模型组、吡拉西坦组（0．62g·kg^-1·d^-1）、AEWH高剂量组（2．0g·kg^-1·d^-1）、AEWH低剂量组（0．5g·kg^-1·d^-1）。采用Aβ1—42小鼠双侧脑室注射诱导AD模型小鼠。小鼠给予AEWH灌胃，连续治疗18d后取材，采用双抗体夹心法测定海马IL-1β水平。与对照组比较，模型组小鼠海马IL-1β水平明显升高（P〈0．05）；与模型组比较，AEWH高剂量组海马IL-1β水平明显降低（P〈0．05）。说明AEWH高剂量（2．0g·kg^-1·d^-1）能降低IL-1β水平，AEWH通过抑制IL-1β在AD治疗中发挥重要作用。
英文摘要：
Male mice were randomly divided into control group, model group, piracetam group ＋（0.62g · kg^-1· d^-1）, AEWH high dose group （2.0g ·kg^-1· d^-1）, AEWH low dose group （0.5g ·kg^-1·d^-1）. A β 1-42 injected mice using two-ventricle induced mouse model of AD. AEWH mice were given orally, 18d drawn after continuous treatment, hippocampal IL-1β levels measured by double antibody sandwich assay. Compared with the control group, model group mouse hippocampal IL-1 β levels were significantly increased （P 〈0.05）. Compared with the model group, AEWH high dose group of hippocampal IL-1β levels were significantly lower （P 〈0.05）. Description AEWH high dose （2.0g· kg^-1 · d^-1） reduces IL-1β levels, AEWH by inhibiting IL-1β play an important role in the treatment of AD.
同期刊论文项目
同项目期刊论文
期刊信息
位置：